April 19, 2017 09:28 AM EDT
R&D

Ul­tragenyx, Ky­owa Hakko Kirin plan a date with the FDA af­ter pos­i­tive PhI­II for X-linked hy­pophos­phatemia

John Carroll

Editor & Founder

Shares of Ul­tragenyx surged about 10% af­ter the biotech re­port­ed clear­ly pos­i­tive Phase III da­ta for their Ky­owa Hakko Kirin-part­nered drug for X-linked hy­pophos­phatemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times